Eyal Talor, Ph.D.
About Eyal Talor, Ph.D.
Chief Scientific Officer, CEL-SCI: Eyal Talor, Ph.D.
Eyal Talor, Ph.D., serves as the Chief Scientific Officer at CEL-SCI, a position he has held since October 2009. He joined the company in October 1993 and advanced from the role of Senior Vice President of Research and Manufacturing. His responsibilities involve overseeing the company's biopharmaceutical research and development initiatives, focusing on immunotherapy applications.
Education and Expertise of Eyal Talor, Ph.D.
Dr. Talor earned his Ph.D. in Microbiology and Immunology from the University of Ottawa in Ontario, Canada. He completed his post-doctoral training in clinical and cellular immunology at The Johns Hopkins University in Baltimore, Maryland. His areas of expertise include clinical immunology, biopharmaceutical research and development, Biologics product development, and immune response assessment. Dr. Talor has over 25 years of experience in these fields.
Career Background of Eyal Talor, Ph.D.
Dr. Talor has held numerous influential roles throughout his career, including Director of R&D and Clinical Development at CBL, Inc., and Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. He also served as a full-time faculty member at The Johns Hopkins University, School of Public Health. Additionally, he has held an Associate teaching position at Johns Hopkins University Medical Institutions.
Contributions and Innovations by Eyal Talor, Ph.D.
Dr. Talor has invented technologies covered by ten issued patents, including those related to Multikine's composition of matter and method of use in cancer, along with two platform Peptide technologies. He is responsible for numerous product and process inventions, as well as pending US and PCT patent applications. His contributions are significant in the realm of clinical immunology and drug development.
Publications and Scientific Work of Eyal Talor, Ph.D.
Dr. Talor is the author of over 25 publications and has published several reviews on immune regulations in clinical immunology. His extensive experience in the design and implementation of pre-clinical and clinical trials (Phase I - III) and his knowledge of GCP requirements underscore his important contributions to scientific literature and research methodologies.